Keep this stock on your watch list.
Revive your portfolio with Baxter International.
A rally in the shares stalled around $180 in December and early January.
Six investment experts look beyond the traditional pharmaceutical names to highlight their favorite sector plays for the coming year.
Two in five Americans are obese. Treatments that target obesity directly could be the next blockbuster pharma category.
The company reported earnings and the shares have rolled over and turned down.
The charts are indicating that the stock's downward trend for much of the last year may be ending.
The charts of the oncology company are nothing but bearish and its stock could be in for more downside action ahead.
We expect Chinese travelers to return in large numbers, as Asian nations slap new restrictions on arrivals from the last major nation to learn to "live with Covid."
The charts indicate an upside breakout could happen soon.